Trial Profile
Phase III pivotal trial of tetracosactide [RE 034] for the treatment of nephrotic syndrome
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 30 Sep 2021
Price :
$35
*
At a glance
- Drugs Tetracosactide (Primary)
- Indications Nephrotic syndrome
- Focus Registrational; Therapeutic Use
- 31 Dec 2013 New trial record